(((Pharma)))
You don’t need jew poison.
Just stop shovelling food in your pie hole.
> (((Pharma)))
You don’t need jew poison.
Just stop shovelling food in your pie hole.
Shares of medical equipment companies specializing in sleep apnea treatments nosedived on Monday after a new study from Eli Lilly and Company revealed that its tirzepatide weight-loss drug significantly reduced the severity of sleep apnea.
On Friday, Eli Lilly announced new results from its SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection to treat moderate-to-severe obstructive sleep apnea, otherwise known as OSA.
Tirzepatide, branded as Mounjaro (a diabetes drug) and Zepbound (a weight loss drug), reduced moderate-to-severe OSA in obese adults with and without positive airway pressure (PAP) therapy.
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy.
In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacy and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo. . .
Archive (archive.today)
>Shares of medical equipment companies specializing in sleep apnea treatments nosedived on Monday after a new study from Eli Lilly and Company revealed that its tirzepatide weight-loss drug significantly reduced the severity of sleep apnea.
>On Friday, Eli Lilly announced new results from its SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection to treat moderate-to-severe obstructive sleep apnea, otherwise known as OSA.
>Tirzepatide, branded as Mounjaro (a diabetes drug) and Zepbound (a weight loss drug), reduced moderate-to-severe OSA in obese adults with and without positive airway pressure (PAP) therapy.
>>Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy.
>>In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacy and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo.
.
.
[Archive](https://archive.today/qtebL)
(post is archived)